OrbiMed Advisors LLC disclosed a 7.2% stake in Scribe Therapeutics, Inc.'s common stock. The filing, dated July 29, 2026, follows Scribe’s IPO, during which OrbiMed-related funds bought additional shares. The investment adds a notable healthcare specialist to Scribe’s holder base and comes as OrbiMed’s Carl L. Gordon sits on Scribe’s board.
Investor Intent
OrbiMed says it bought the shares for investment and not to take control of Scribe Therapeutics. The firm adds it could buy more stock or sell shares in the future as it reviews the company’s performance and market conditions.
Key quotes: "The Shares ... were acquired for the purpose of making an investment ... and not with the intention of acquiring control." OrbiMed also notes it "may acquire Shares ... or ... dispose of" them based on its ongoing review.
Investor's Background
OrbiMed Advisors LLC is a Delaware limited liability company and a registered investment adviser focused on healthcare. The firm invests across venture capital, private equity, and public equities in biotech, pharmaceuticals, and medical devices. OrbiMed is known for backing innovative drug developers and has led or supported numerous notable biotech IPOs.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.